BFAR Promotes Neutrophil Infiltration and Immunosuppressive Reprogramming through the PRP19–YBX1 Axis to Induce Immune Evasion in Gastric Cancer
The immunosuppressive tumor microenvironment remains a major barrier to effective immunotherapy in gastric cancer. In this study, we identified the E3 ubiquitin ligase BFAR as a critical regulator of neutrophil-mediated immune evasion through the S100A8/A9-BFAR-PRP19-YBX1 signaling axis. Multiomics analyses revealed that BFAR is overexpressed in gastric cancer and correlates with poor prognosis. Functional studies demonstrated that BFAR knockdown suppressed tumor growth by reducing neutrophil infiltration and immunosuppressive reprogramming to restore CD8+ T-cell function. Mechanistically, BFAR mediated K48-linked ubiquitination and degradation of PRP19, leading to stabilization of the oncoprotein YBX1, which transcriptionally upregulated neutrophil-recruiting chemokines CXCL1/CXCL3. Infiltrating neutrophils secreted S100A8/A9, which activated NF-κB to induce BFAR expression in tumor cells and created a feed-forward loop that sustains an immunosuppressive tumor microenvironment. Furthermore, BFAR promoted neutrophil PD-L1 expression via GM-CSF, reinforcing T-cell exhaustion. Clinically, BFAR expression correlated with neutrophil infiltration and poor response to anti-PD-1 therapy, whereas its inhibition synergizes with immune checkpoint blockade in preclinical models. Our work unveils BFAR as a central orchestrator of neutrophil-driven immunosuppression and proposes targeting this axis to enhance immunotherapy efficacy in gastric cancer.
Authors
- Tetsuya Tsukamoto (ORCID: https://orcid.org/0000-0002-7502-8724)
- Feiyue Zhang (ORCID: https://orcid.org/0000-0001-8682-9941)
- Masami Yamamoto (ORCID: https://orcid.org/0000-0003-2071-7730)
- Yunlan Zhou (ORCID: https://orcid.org/0000-0001-8957-1245)
- Wei Liang (ORCID: https://orcid.org/0000-0002-4153-0775)
- Bei Miao (ORCID: https://orcid.org/0000-0002-9017-8130)
- Sachiyo Nomura (ORCID: https://orcid.org/0000-0003-4293-6205)
- Sujuan Fei (ORCID: https://orcid.org/0000-0002-7828-028X)
- Ma Xin (ORCID: https://orcid.org/0000-0002-6901-4975)
- Yingying Chen (ORCID: https://orcid.org/0009-0004-6422-8810)
- Li Li (ORCID: https://orcid.org/0000-0002-9702-4601)
- Pengbo Zhang (ORCID: https://orcid.org/0000-0002-8519-3125)
- Yumei Liu (ORCID: https://orcid.org/0009-0002-0284-260X)
- Jiajia Wang (ORCID: https://orcid.org/0000-0003-2831-9550)
- Juan Wang (ORCID: https://orcid.org/0000-0001-9452-7900)
Institutions
- Nippon Veterinary and Life Science University (JP)
- Fujita Health University (JP)
- Xuzhou Medical College (CN)
- Shanghai Jiao Tong University (CN)
- XinHua Hospital (CN)
- Hoshi University (JP)
- Huadong Hospital (CN)
- Affiliated Hospital of Xuzhou Medical College (CN)
- Shanghai Clinical Research Center (CN)
Publication Details
- Journal
- Cancer Immunology Research
- Published
- 2025-09-18
- DOI
- https://doi.org/10.1158/2326-6066.cir-24-1011
- Citations
- 2
- Primary Topic
- Immune cells in cancer
- Type
- article
- Field-Weighted Citation Impact
- 1.59